Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor... see more

Recent & Breaking News (NDAQ:BCRX)

BioCryst to Report First Quarter 2026 Financial Results on May 6

GlobeNewswire 7 days ago

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

GlobeNewswire April 6, 2026

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 3, 2026

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 4, 2026

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire February 26, 2026

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire February 17, 2026

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

GlobeNewswire February 11, 2026

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

GlobeNewswire February 5, 2026

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 5, 2026

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema 

GlobeNewswire January 23, 2026

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

GlobeNewswire January 12, 2026

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 6, 2026

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2026

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years

GlobeNewswire December 12, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 4, 2025

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

GlobeNewswire December 3, 2025

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Business Wire November 12, 2025

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

GlobeNewswire November 6, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 5, 2025

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire November 5, 2025

Podcasts